Adcentrx begins patient dosing in phase 1a/b study of ADRX-0405, a potential first-in-class ADC targeting STEAP1 to treat advanced solid tumours: San Diego, California Wednesday, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback